← Back to Search

Antifungal

Terbinafine Gel for Toenail Fungus

Phase 2
Waitlist Available
Led By Terry M. Jones, MD
Research Sponsored by Hallux, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with DLSO of at least one great toe
Patients with DLSO in the target toe confirmed by positive KOH and positive fungal culture for dermatophytes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights

Study Summary

This trial is testing a new gel to treat a type of fungal nail infection. The goal is to see if the gel is effective, safe, and well tolerated.

Who is the study for?
This trial is for men and women aged 18-75 with toenail fungus, specifically on the big toe. Participants must not use other nail treatments during the study and should have a confirmed fungal infection by lab tests. Those with uncontrolled diabetes, recent participation in other drug trials, or who used antifungal treatments recently cannot join.Check my eligibility
What is being tested?
The trial is testing Hallux Terbinafine Subungual Gel (HSG) to treat toenail fungus over a period of 44 weeks. It aims to assess how effective and safe HSG is when applied directly under the toenail, as well as understanding how the body processes it.See study design
What are the potential side effects?
While specific side effects are not listed here, common side effects of topical antifungal treatments like HSG can include skin irritation, redness, itching or burning at the application site. Systemic side effects are less common but may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a fungal infection in at least one of my big toes.
Select...
My toe fungus was confirmed by lab tests.
Select...
I am between 18 and 75 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Complete Cure at Week 52 in the Target Toe
Secondary outcome measures
Clinical Cure in the Target Toe
Mycological Cure in the Target Toe
Positive Response in the Target Toe
Other outcome measures
Nail Pharmacokinetics
Patient Global Assessment
Plasma Pharmacokinetics
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: HSGExperimental Treatment1 Intervention
Hallux terbinafine subungual gel

Find a Location

Who is running the clinical trial?

Hallux, Inc.Lead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
Terry M. Jones, MDPrincipal InvestigatorJ&S Studies
Daniel P. Mallett, DPMPrincipal InvestigatorFront Range Foot and Ankle Clinic

Media Library

Hallux Terbinafine Subungual Gel (Antifungal) Clinical Trial Eligibility Overview. Trial Name: NCT05135910 — Phase 2
Toenail Fungus Research Study Groups: HSG
Toenail Fungus Clinical Trial 2023: Hallux Terbinafine Subungual Gel Highlights & Side Effects. Trial Name: NCT05135910 — Phase 2
Hallux Terbinafine Subungual Gel (Antifungal) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05135910 — Phase 2
~3 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top